

## Supplementary Information

### Supplementary Table S1: Comparison of cancer-specific characteristics in wave 1 and

2. Data is shown as n (%). P-value significance level is indicated for the combined cancer cohort in each wave.

	Wave 1 (n = 94)	Wave 2 (n = 113)	p-value
<b>Primary site</b>			
<b>Gastrointestinal</b>	23 (24.5%)	29 (25.7%)	0.84
<b>Gynaecological</b>	9 (9.6%)	11 (9.7%)	0.97
<b>Genitourinary</b>	24 (25.5%)	27 (23.9%)	0.79
<b>Thoracic</b>	15 (16.0%)	13 (11.5%)	0.35
<b>Breast</b>	8 (8.5%)	14 (12.4%)	0.37
<b>Other</b>	15 (16.0%)	19 (16.8%)	0.86
<b>Active malignancy</b>	58 (61.7%)	70 (61.9%)	0.84
<b>Remission</b>	50 (53.2%)	41 (36.3%)	
<b>Metastatic malignancy</b>	19 (20.2%)	28 (24.8%)	0.42
<b>SACT</b>	25 (26.6%)	33 (29.2%)	0.72
<b>Cytotoxic chemotherapy</b>	16 (17.0%)	24 (21.2%)	0.44
<b>Palliative chemotherapy</b>	9 (9.6%)	16 (14.2%)	0.31
<b>Immunotherapy</b>	4 (4.3%)	1 (0.9%)	0.11
<b>Targeted therapy</b>	1 (1.1%)	7 (6.2%)	0.06
<b>Endocrine therapy</b>	8 (8.5%)	7 (6.2%)	0.51
<b>Surgery</b>	3 (3.2%)	5 (4.4%)	0.66

### Supplementary Table S2: Univariate analysis of general and cancer-specific variables

among patients with cancer. Table shows the hazard ratios (HR) from univariate analyses of risk factors associated with mortality in COVID-19. 95% confidence interval for each HR is shown alongside p-value.

Title	HR (95% CI for HR)	p-value
<b>Age (every 10 years)</b>	1.41 (1.15-1.73)	<0.001
<b>Male sex</b>	1.51 (0.86-2.66)	0.15
<b>South Asian</b>	1.79 (0.9-3.56)	0.10
<b>Black</b>	0.5 (0.15-1.59)	0.24
<b>White</b>	0.73 (0.43-1.25)	0.25
<b>Other</b>	1.54 (0.75-3.14)	0.24
<b>BMI</b>	0.98 (0.94-1.03)	0.43
<b>Ex-or-active smoker</b>	1.07 (0.63-1.84)	0.80

<b>Dementia</b>	1 (0.4-2.5)	1.00
<b>Diabetes</b>	1.01 (0.55-1.84)	0.98
<b>Immunosuppression</b>	3.17 (0.77-13.13)	0.11
<b>Congestive cardiac failure</b>	0.9 (0.33-2.49)	0.84
<b>Liver impairment</b>	0.85 (0.12-6.13)	0.87
<b>Hypertension</b>	1.55 (0.92-2.59)	0.10
<b>Peripheral vascular disease</b>	1.05 (0.25-4.29)	0.95
<b>Stroke</b>	1.58 (0.8-3.14)	0.19
<b>Chronic lung disease</b>	1.1 (0.56-2.18)	0.78
<b>Chronic kidney disease</b>	1.24 (0.61-2.52)	0.56
<b>Steroid therapy in progress</b>	1.08 (0.26-4.42)	0.92
<b>Cardiovascular disease</b>	1.32 (0.73-2.38)	0.35
<b>Other co-morbidity</b>	0.8 (0.45-1.4)	0.43
<b>Wave 2</b>	0.41 (0.23-0.71)	<0.01
<b>Gastrointestinal</b>	1.16 (0.67-2.03)	0.60
<b>Gynaecological</b>	1.01 (0.36-2.78)	0.99
<b>Genito-urinary</b>	1.34 (0.77-2.34)	0.31
<b>Thoracic</b>	0.97 (0.46-2.05)	0.94
<b>Breast</b>	0.66 (0.24-1.84)	0.43
<b>Other</b>	0.61 (0.26-1.42)	0.25
<b>Adenocarcinoma</b>	1.03 (0.6-1.76)	0.92
<b>Squamous</b>	0.83 (0.41-1.71)	0.62
<b>Other</b>	1.11 (0.61-1.99)	0.74
<b>Metastatic disease</b>	1.61 (0.91-2.83)	0.10
<b>Any anti-cancer therapy</b>	1.11 (0.64-1.95)	0.71
<b>Systemic anti-cancer therapy</b>	1.44 (0.82-2.53)	0.20
<b>Cytotoxic chemotherapy</b>	1.17 (0.6-2.26)	0.64
<b>Neo/adjuvant chemotherapy</b>	0.57 (0.14-2.34)	0.43
<b>Palliative chemotherapy</b>	1.54 (0.75-3.13)	0.24
<b>Immunotherapy</b>	1.45 (0.35-5.94)	0.61
<b>Targeted therapy</b>	0.61 (0.08-4.41)	0.62
<b>Endocrine therapy</b>	1.64 (0.71-3.83)	0.25
<b>Radiotherapy</b>	1.46 (0.46-4.69)	0.52
<b>Surgery</b>	0.31 (0.04-2.28)	0.25